Life Science Washington, the state’s life science industry association, today published its first annual “Investor Report,” detailing the life science investment trends in Washington state over the last year. The report, compiled from Pitchbook, S&P Global Market Intelligence and other publicly disclosed data, shows strong financial momentum for Washington life science companies with more than 180 investors worldwide making deals…
Read More
Zymeworks signed a deal with Jazz Pharmaceuticals to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, which targets the cancer marker HER2. Zymeworks will receive an upfront payment of $50 million and a second payment of $325 million, at Jazz’s option, following the release of topline data from an ongoing clinical trial. That trial is testing the agent as a second-line treatment for…
Read More
The University of Washington recently hosted a panel of five entrepreneurs to discuss what it takes to launch a life sciences company. Panelists shared how they got a foothold in the industry and some of the things they learned along the way. The panel was moderated by Teddy Johnson, director of technology development at the UW’s Institute of Translational Health Sciences. ITHS…
Read More
Omnipose, a deep learning software, is helping to solve the challenge of identifying varied and miniscule bacteria in microscopy images. It has gone beyond this initial goal to identify several other types of tiny objects in micrographs. The UW Medicine microbiology lab of Joseph Mougous and the University of Washington physics and bioengineering lab of Paul A. Wiggins tested the tool. It was developed…
Read More
Bone marrow transplants have transformed care for patients with blood cancers because donated immune cells often prevent cancer relapse by killing off residual malignant cells. One of the drawbacks of the treatment is graft-vs.-host disease — a common side effect that occurs when the transplanted cells see the recipient’s healthy tissues as foreign and attack them. These attacks can be short-lived and…
Read More

Dr. Alice Kane Joins ISB as Ling/Obrzut Assistant Professor

ISB is excited to announce the arrival of our newest faculty member, Ling/Obrzut Assistant Professor Dr. Alice Kane. Her lab will investigate the biological determinants of frailty in both males and females.  Following is a Q&A with Kane that delves into her research career to date, her research areas of interest, and much more. 
Read More
Seattle-area microbiome and diagnostics startup Viome Life Sciences is raising more cash, according to a new regulatory filing. The filing shows $67 million raised of a larger round. We’ve reached out to Viome to learn more and will update when we hear back. Viome sells a kit to determine the microbial composition of stool samples and recommends “precision” supplements and probiotics based on…
Read More
Today, Seattle Children’s announced the appointment of Dr. Eric Tham as its new senior vice president and chief research operations officer. Tham will focus on research administration, finance, operations and continue broader research leadership, effective immediately. Since 2021, Tham has served as interim senior vice president of Seattle Children’s Research Institute. “I’m excited to help guide the research division as…
Read More